Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection

Abstract

The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.

Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek

“…Contrary to our expectation, the intradermal administration did not exhibit a faster clearance half-life (2.62 +/− 0.55 hr) than Phase I study group that utilized a periturmoral/intradermal injection [13], which exhibited a clearance half-life of 2.72 +/− 1.57 hr. This was also true for our melanoma study [12], where the measured clearance half-life was 2.05 +/− 0.89 hr.…”

“…The mean sentinel lymph node accumulation after a 1-nmole dose of Lymphoseek using a standard mapping protocol for SLN of melanoma [12] was 0.49 ± 0.59 percent of injected dose. A breast cancer mapping protocol using an intradermal/periturmoral administration of Lymphoseek [13] yielded mean SLN uptakes of 0.55 ± 0.43 %. These values are lower than the means 1.1 ± 0.5 % exhibited by the Lymphoseek group of this study; the differences are not, however, significant.…”

“…In women with breast cancer, Lymphoseek demonstrated significantly faster clearance from the injection site and equivalent sentinel lymph node accumulation [13]. No adverse events or clinically significant changes in clinical and laboratory values were observed.…”

“…This study used the same Lymphoseek preparation as our Phase I Breast cancer [1,13] and melanoma trials [12]. The mean molecular diameter was 7.0 nanometers and the average molecular weight was 28,200 grams per mole.…”

“…The injection site clearance rate constant k c and half-life T c of Lymphoseek and filtered [ 99m Tc]sulfur colloid were calculated using decay-corrected counts obtained from the nuclear images of the injection site. [13] …”